Index DJIA, S&P 500
P/E 21.43
EPS (ttm) 5.40
Insider Own 0.10%
Shs Outstand 2.53B
Perf Week -0.81%
Market Cap 293.13B
Forward P/E 11.88
EPS next Y 9.74
Insider Trans 0.00%
Shs Float 2.53B
Perf Month 0.95%
Income 13.74B
PEG -
EPS next Q 1.74
Inst Own 79.37%
Short Float 0.98%
Perf Quarter -12.05%
Sales 62.19B
P/S 4.71
EPS this Y 431.22%
Inst Trans 0.64%
Short Ratio 2.56
Perf Half Y -5.81%
Book/sh 17.19
P/B 6.73
EPS next Y 21.37%
ROA 12.65%
Short Interest 24.81M
Perf Year 6.04%
Cash/sh 4.50
P/C 25.72
EPS next 5Y -
ROE 33.39%
52W Range 99.14 - 134.63
Perf YTD 6.07%
Dividend Est. 3.14 (2.71%)
P/FCF 22.30
EPS past 5Y -42.70%
ROI 17.54%
52W High -14.11%
Beta 0.41
Dividend TTM 3.04 (2.63%)
Quick Ratio 1.22
Sales past 5Y 7.72%
Gross Margin 72.33%
52W Low 16.64%
ATR (14) 2.51
Dividend Ex-Date Sep 16, 2024
Current Ratio 1.47
EPS Y/Y TTM 340.50%
Oper. Margin 26.04%
RSI (14) 44.85
Volatility 2.70% 1.71%
Employees 72000
Debt/Eq 0.87
Sales Y/Y TTM 8.43%
Profit Margin 22.09%
Recom 1.42
Target Price 140.05
Option/Short Yes / Yes
LT Debt/Eq 0.80
EPS Q/Q 191.12%
Payout 2065.60%
Rel Volume 0.97
Prev Close 115.41
Sales Surprise 1.53%
EPS Surprise 5.17%
Sales Q/Q 7.25%
Earnings Jul 30 BMO
Avg Volume 9.68M
Price 115.64
SMA20 -0.20%
SMA50 -3.49%
SMA200 -4.95%
Trades
Volume 6,259,515
Change 0.20%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-11-24 Downgrade
Societe Generale
Hold → Sell
$104
Jan-04-24 Upgrade
TD Cowen
Market Perform → Outperform
$125 → $135
Nov-09-23 Initiated
Deutsche Bank
Buy
$115
Oct-27-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$132
Oct-20-23 Upgrade
UBS
Neutral → Buy
$117 → $122
Jul-14-23 Initiated
HSBC Securities
Hold
$123
Apr-13-23 Upgrade
Citigroup
Neutral → Buy
$105 → $130
Mar-28-23 Downgrade
Societe Generale
Buy → Hold
Mar-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$120 → $115
Mar-06-23 Initiated
Jefferies
Buy
$125
Feb-22-23 Upgrade
Wolfe Research
Peer Perform → Outperform
$127
Jan-04-23 Upgrade
BofA Securities
Neutral → Buy
$110 → $130
Nov-18-22 Initiated
Credit Suisse
Outperform
$120
Oct-10-22 Upgrade
Guggenheim
Neutral → Buy
Sep-14-22 Upgrade
Berenberg
Hold → Buy
$95 → $100
Jul-06-22 Upgrade
Daiwa Securities
Neutral → Buy
$89 → $102
Jun-06-22 Resumed
SVB Leerink
Outperform
$102
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$80
Dec-17-21 Initiated
Goldman
Buy
$93
Dec-16-21 Initiated
Daiwa Securities
Neutral
$70
Show Previous Ratings
Sep-09-24 01:55PM
(The Wall Street Journal)
09:59AM
08:02AM
Sep-07-24 11:30AM
Sep-06-24 06:14PM
12:10PM
Loading…
12:10PM
Sep-05-24 07:00AM
04:32AM
Sep-04-24 03:00PM
06:45AM
06:40AM
04:12AM
(Pharmaceutical Technology)
Sep-03-24 11:32PM
01:22PM
(The Wall Street Journal)
09:40AM
08:10AM
Loading…
08:10AM
06:45AM
Aug-29-24 10:35AM
09:33AM
07:30AM
06:45AM
06:30AM
Aug-28-24 04:52AM
Aug-27-24 08:52AM
07:35AM
06:45AM
05:32AM
Aug-26-24 03:22PM
(Pharmaceutical Technology)
12:00PM
06:45AM
02:10PM
Loading…
Aug-23-24 02:10PM
09:00AM
Aug-22-24 07:00AM
Aug-21-24 09:29AM
Aug-19-24 08:04AM
Aug-17-24 03:21PM
Aug-16-24 08:54PM
06:09PM
Aug-15-24 05:30PM
12:34PM
10:49AM
07:49AM
Aug-14-24 06:15AM
Aug-09-24 03:33PM
(Pharmaceutical Technology)
03:18PM
08:09AM
(The Wall Street Journal)
06:45AM
06:32AM
05:59AM
Aug-08-24 12:23PM
09:00AM
06:45AM
Aug-07-24 07:57AM
Aug-06-24 09:00AM
06:45AM
Aug-02-24 06:00PM
02:22PM
Aug-01-24 08:00AM
Jul-31-24 09:53AM
(Pharmaceutical Technology)
07:33AM
03:20AM
(The Wall Street Journal)
01:58AM
(Thomson Reuters StreetEvents)
Jul-30-24 02:15PM
01:30PM
12:09PM
12:05PM
12:00PM
11:40AM
11:25AM
10:54AM
(Investor's Business Daily)
10:36AM
(The Wall Street Journal)
10:35AM
10:09AM
08:45AM
07:17AM
06:45AM
(Associated Press Finance)
06:32AM
06:32AM
06:30AM
03:28AM
Jul-26-24 06:50AM
Jul-24-24 05:12AM
Jul-23-24 03:04PM
12:52PM
11:17AM
09:30AM
07:01AM
06:45AM
03:52AM
Jul-18-24 09:00AM
09:00AM
Jul-16-24 04:52PM
01:33PM
11:41AM
06:45AM
05:10AM
Jul-12-24 05:46PM
05:04PM
11:33AM
(Pharmaceutical Technology)
06:45AM
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Guindo Chirfi Chief Marketing Officer Aug 05 '24 Option Exercise 115.20 36,901 4,250,995 57,782 Aug 06 12:20 PM Smart Dalton SVP Fin. - Global Controller May 03 '24 Option Exercise 128.26 2,046 262,420 4,708 May 06 04:10 PM Smart Dalton SVP Fin. - Global Controller May 04 '24 Option Exercise 127.51 612 78,036 4,730 May 06 04:10 PM DeLuca Richard R. EVP&Pres, Merck Animal Heallth May 04 '24 Option Exercise 127.51 27,126 3,458,836 163,720 May 06 04:08 PM Klobuchar Michael A EVP - Chief Strategy Officer May 04 '24 Option Exercise 127.51 887 113,101 24,058 May 06 04:06 PM Oosthuizen Johannes Jacobus President, U.S. Market May 04 '24 Option Exercise 127.51 912 116,289 24,271 May 06 04:01 PM Romanelli Joseph President, Human Health Int?l May 02 '24 Option Exercise 128.80 2,262 291,346 21,831 May 02 04:29 PM Smart Dalton SVP Fin. - Global Controller May 02 '24 Option Exercise 128.80 381 49,073 3,048 May 02 04:23 PM Merck & Co., Inc. 10% Owner Mar 11 '24 Buy 23.00 21,397,205 492,135,715 1,000 Mar 11 03:27 PM Litchfield Caroline EVP & CFO Feb 14 '24 Option Exercise 58.08 38,291 2,223,941 89,199 Feb 15 04:03 PM Litchfield Caroline EVP & CFO Feb 14 '24 Sale 125.50 38,291 4,805,520 50,908 Feb 15 04:03 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Option Exercise 74.18 150,000 11,127,160 498,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Option Exercise 73.73 85,021 6,268,598 433,348 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 13 '24 Sale 125.85 150,000 18,877,424 348,327 Feb 15 04:01 PM Davis Robert M Chairman, CEO & President Feb 14 '24 Sale 125.40 85,021 10,661,574 348,327 Feb 15 04:01 PM Romanelli Joseph President, Human Health Int?l Feb 13 '24 Sale 124.89 1,000 124,888 19,569 Feb 14 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Option Exercise 62.07 14,702 912,553 60,944 Feb 12 04:03 PM Li Dean Y Executive VP & President, MRL Feb 09 '24 Sale 125.50 14,702 1,845,083 46,242 Feb 12 04:03 PM Williams David Michael EVP,Chief Info&Digital Officer Feb 07 '24 Sale 127.57 1,451 185,108 19,812 Feb 08 04:04 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Option Exercise 78.80 20,937 1,649,906 42,286 Feb 05 04:01 PM Oosthuizen Johannes Jacobus President, U.S. Market Feb 02 '24 Sale 127.17 18,959 2,411,111 23,327 Feb 05 04:01 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Option Exercise 73.65 32,994 2,430,159 74,313 Feb 02 04:07 PM MIZELL STEVEN EVP, Chief HR Officer Feb 02 '24 Sale 126.65 50,694 6,420,349 23,619 Feb 02 04:07 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Option Exercise 87.10 19,417 1,691,221 78,557 Feb 02 04:05 PM Zachary Jennifer EVP, General Counsel Feb 02 '24 Sale 126.97 49,499 6,284,779 29,058 Feb 02 04:05 PM Oosthuizen Johannes Jacobus President, U.S. Market Nov 09 '23 Sale 102.38 2,081 213,061 18,191 Nov 13 07:36 AM DeLuca Richard R. EVP&Pres, Merck Animal Heallth Nov 08 '23 Sale 105.03 43,823 4,602,668 111,764 Nov 09 09:04 AM Oosthuizen Johannes Jacobus President, U.S. Market Oct 30 '23 Option Exercise 102.82 915 94,080 20,723 Oct 31 11:08 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite